Cargando…

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

OBJECTIVE: Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not been evaluated. METHODS: In Giant-Cell Arteritis Ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stone, John H, Spotswood, Helen, Unizony, Sebastian H, Aringer, Martin, Blockmans, Daniel , Brouwer, Elisabeth, Cid, Maria C, Dasgupta, Bhaskar, Rech, Juergen, Salvarani, Carlo, Spiera, Robert, Bao, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258533/ https://www.ncbi.nlm.nih.gov/pubmed/34718434 http://dx.doi.org/10.1093/rheumatology/keab780

Ejemplares similares

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
por: Unizony, Sebastian, et al.
Publicado: (2021)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018)

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2020)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series
por: Saha, Pratyasha, et al.
Publicado: (2022)

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
por: Prieto-González, Sergio, et al.
Publicado: (2017)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2023)

Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022)

Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)

Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)

Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
por: Ohta, Ryuichi, et al.
Publicado: (2023)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2021)

Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
por: Seitz, Luca, et al.
Publicado: (2021)

The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
por: Patel, Naomi J., et al.
Publicado: (2021)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool
por: Sebastian, Alwin, et al.
Publicado: (2020)

Updates on the diagnosis and monitoring of giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2023)

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
por: Loricera, Javier, et al.
Publicado: (2022)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
por: de Boysson, Hubert, et al.
Publicado: (2021)

Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
por: Hara, Kazusato, et al.
Publicado: (2021)

Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
por: Cho, Young Min, et al.
Publicado: (2023)

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
por: Best, Jennie H., et al.
Publicado: (2019)

Tocilizumab for faster and safer remission of Takayasu’s arteritis
por: Liao, Hua, et al.
Publicado: (2022)

Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients
por: Regola, Francesca, et al.
Publicado: (2020)

Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy
por: Venkateswaran, Niranjani, et al.
Publicado: (2020)

Large-vessel involvement is predictive of multiple relapses in giant cell arteritis
por: de Mornac, Donatienne, et al.
Publicado: (2021)

Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis
por: van Sleen, Yannick, et al.
Publicado: (2017)

Patients’ Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study
por: Dumain, Cyril, et al.
Publicado: (2022)

Exacerbation of Ulcerative Colitis with Tocilizumab: A Report of Two Cases, One with Takayasu Arteritis and the Other with Relapsing Polychondritis
por: Hanioka, Yusuke, et al.
Publicado: (2020)

Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis
por: Sebastian, Alwin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vgafp83r2s3a2l14boelpk2uui